U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809400) titled 'A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease' on Jan. 31.
Brief Summary: The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: LY4006896
Administered intravenously (IV)
DRUG: Placebo
Administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....